Cargando…
Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial
INTRODUCTION: This study was performed to evaluate the degree of 3-day chemotherapy-induced nausea and vomiting (CINV) in children with cancer who received highly emetogenic chemotherapy (HEC) to ascertain the efficacy of aprepitant single-dose on dayL 1 plus granisetron and dexamethasone (DEX). MET...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499563/ https://www.ncbi.nlm.nih.gov/pubmed/35428609 http://dx.doi.org/10.1016/j.htct.2022.02.004 |
_version_ | 1785105736177549312 |
---|---|
author | Eghbali, Aziz Kohpar, Fatemeh Khazaei Ghaffari, Kazem Afzal, Roghayeh Rahimi Eghbali, Aygin Ghasemi, Ali |
author_facet | Eghbali, Aziz Kohpar, Fatemeh Khazaei Ghaffari, Kazem Afzal, Roghayeh Rahimi Eghbali, Aygin Ghasemi, Ali |
author_sort | Eghbali, Aziz |
collection | PubMed |
description | INTRODUCTION: This study was performed to evaluate the degree of 3-day chemotherapy-induced nausea and vomiting (CINV) in children with cancer who received highly emetogenic chemotherapy (HEC) to ascertain the efficacy of aprepitant single-dose on dayL 1 plus granisetron and dexamethasone (DEX). METHODS: This clinical trial study was conducted on 120 patients in the age range of 5 to 18 years old who received chemotherapy. Patients were divided into two groups; Group A received aprepitant at 125 mg/kg on day 1 orally, followed by 80 mg/kg daily on days 2 and 3 and Group B received a single dose of aprepitant 125 mg/kg on day 1 orally and placebo on days 2 and 3. All groups received granisetron 3 mg/m(2) on day 1 and DEX on days 1 to 3. The primary and secondary endpoints were to evaluate the proportion of patients with acute, delayed and overall CINV within each group. RESULTS: There were no significant differences between the two groups for vomiting, nausea or the use of rescue therapy. The number of patients without vomiting on day 1 was similar in both groups (96.5% vs. 98.3%, respectively; p = 0.848). CONCLUSION: According to the results of this study, a single dose of aprepitant 125 mg/kg was as effective as administering three doses of aprepitant on 3 days. Therefore, the use of a single dose of aprepitant in combination with other standard treatment regimens to prevent CINV in children who received HEC was safe and efficacious and can be beneficial. |
format | Online Article Text |
id | pubmed-10499563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Sociedade Brasileira de Hematologia e Hemoterapia |
record_format | MEDLINE/PubMed |
spelling | pubmed-104995632023-09-15 Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial Eghbali, Aziz Kohpar, Fatemeh Khazaei Ghaffari, Kazem Afzal, Roghayeh Rahimi Eghbali, Aygin Ghasemi, Ali Hematol Transfus Cell Ther Original Article INTRODUCTION: This study was performed to evaluate the degree of 3-day chemotherapy-induced nausea and vomiting (CINV) in children with cancer who received highly emetogenic chemotherapy (HEC) to ascertain the efficacy of aprepitant single-dose on dayL 1 plus granisetron and dexamethasone (DEX). METHODS: This clinical trial study was conducted on 120 patients in the age range of 5 to 18 years old who received chemotherapy. Patients were divided into two groups; Group A received aprepitant at 125 mg/kg on day 1 orally, followed by 80 mg/kg daily on days 2 and 3 and Group B received a single dose of aprepitant 125 mg/kg on day 1 orally and placebo on days 2 and 3. All groups received granisetron 3 mg/m(2) on day 1 and DEX on days 1 to 3. The primary and secondary endpoints were to evaluate the proportion of patients with acute, delayed and overall CINV within each group. RESULTS: There were no significant differences between the two groups for vomiting, nausea or the use of rescue therapy. The number of patients without vomiting on day 1 was similar in both groups (96.5% vs. 98.3%, respectively; p = 0.848). CONCLUSION: According to the results of this study, a single dose of aprepitant 125 mg/kg was as effective as administering three doses of aprepitant on 3 days. Therefore, the use of a single dose of aprepitant in combination with other standard treatment regimens to prevent CINV in children who received HEC was safe and efficacious and can be beneficial. Sociedade Brasileira de Hematologia e Hemoterapia 2023 2022-03-29 /pmc/articles/PMC10499563/ /pubmed/35428609 http://dx.doi.org/10.1016/j.htct.2022.02.004 Text en © 2022 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Eghbali, Aziz Kohpar, Fatemeh Khazaei Ghaffari, Kazem Afzal, Roghayeh Rahimi Eghbali, Aygin Ghasemi, Ali Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial |
title | Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial |
title_full | Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial |
title_fullStr | Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial |
title_full_unstemmed | Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial |
title_short | Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial |
title_sort | evaluating aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: a triple-blinded randomized clinical trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499563/ https://www.ncbi.nlm.nih.gov/pubmed/35428609 http://dx.doi.org/10.1016/j.htct.2022.02.004 |
work_keys_str_mv | AT eghbaliaziz evaluatingaprepitantsingledoseplusgranisetronanddexamethasoneinchildrenreceivinghighlyemetogenicchemotherapyforthepreventionofchemotherapyinducednauseaandvomitingatripleblindedrandomizedclinicaltrial AT kohparfatemehkhazaei evaluatingaprepitantsingledoseplusgranisetronanddexamethasoneinchildrenreceivinghighlyemetogenicchemotherapyforthepreventionofchemotherapyinducednauseaandvomitingatripleblindedrandomizedclinicaltrial AT ghaffarikazem evaluatingaprepitantsingledoseplusgranisetronanddexamethasoneinchildrenreceivinghighlyemetogenicchemotherapyforthepreventionofchemotherapyinducednauseaandvomitingatripleblindedrandomizedclinicaltrial AT afzalroghayehrahimi evaluatingaprepitantsingledoseplusgranisetronanddexamethasoneinchildrenreceivinghighlyemetogenicchemotherapyforthepreventionofchemotherapyinducednauseaandvomitingatripleblindedrandomizedclinicaltrial AT eghbaliaygin evaluatingaprepitantsingledoseplusgranisetronanddexamethasoneinchildrenreceivinghighlyemetogenicchemotherapyforthepreventionofchemotherapyinducednauseaandvomitingatripleblindedrandomizedclinicaltrial AT ghasemiali evaluatingaprepitantsingledoseplusgranisetronanddexamethasoneinchildrenreceivinghighlyemetogenicchemotherapyforthepreventionofchemotherapyinducednauseaandvomitingatripleblindedrandomizedclinicaltrial |